OK, I'll tone it down, lol. Wonder if he's still in - I notice he didn't post today. :)
ZIOPHARM is developing Ad-RTS-IL-12 using Intrexon Corporation's (NYSE:XON) RheoSwitch Therapeutic System® (RTS®) platform to control the expression of interleukin-12 and enable its safe and effective delivery as an anti-tumor agent. ZIOPHARM and Intrexon recently presented preclinical study results at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, supporting the capability of Ad-RTS-IL-12 in the treatment of glioma. These studies showed both the ability for veledimex to penetrate the blood brain barrier and a dose-related increase in survival in a mouse GL-261 glioma model. Animals treated with Ad-RTS-IL-12 survived throughout the duration of the study (100% survival at 75 days) with no significant adverse clinical signs observed. In contrast, the mean survival in the control groups was 22 (±3) days. These findings support localized regulated IL-12 production as an approach for the treatment of malignant glioma.
"The NIH Committee's decision is an important step forward in bringing Ad-RTS-IL-12, a potentially transformative new DNA-based therapeutic, to the treatment of gliomas," said Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations at ZIOPHARM. "In tumor models, Ad-RTS-IL-12 and veledimex demonstrate a unique ability to overcome these barriers by localizing and tightly controlling expression of the potent cytokine interleukin-12. Our preclinical data to date demonstrate both a precisely controlled biologic response using this gene expression system as well as a remarkable effect on these tumors, suggesting further evaluation in the clinic. We expect to initiate a multicenter Phase 1 study in the first half of next year, and look forward to understanding the clinical potential of this therapy in brain cancers."
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral activator, in subjects with recurrent or progressive glioblastoma or grade III malignant glioma (brain cancer). ZIOPHARM has announced plans to launch a Phase 1 study of Ad-RTS-IL-12 in malignant glioma in the first half of 2014. The Company is currently studying Ad-RTS-IL-12 in Phase 2 studies in melanoma and breast cancer.
"Malignant gliomas remain one of the deadliest forms of cancer. The stimulation of an immune response is a novel and intriguing therapeutic approach," said E. Antonio Chiocca , M.D., Ph.D., Chairman, Department of Neurosurgery , and Co-Director of the Institute for the Neurosciences , Brigham and Women's Hospital/ Dana Farber Cancer Institute , and Harvey Cushing Professor of Neurosurgery, Harvard Medical School . "Important variables to the efficacy and safety of such therapies include the immune-privileged status of the central nervous system, the processes that contribute to the suppression of immune responses and the ability to modulate a brain tumor specific immune response.
Thanks joel. Sorry about your loss. Without going into a lot of teaching-talk, let me just say this. If you weren't already a long, when these things pop, you don't want to jump in like that. The first wave is always followed by a pullback, as a lot of those already in reach to take profits (not to mention the daytraders doing what they do). It's on that pb (or even a later one) that you want to get in, if you're intent on getting in. If you had had some patience, you'd be telling me you got in at 26 and were now happy with it at 30. :)
Also, think about buying in thirds or quarters. Decide how much (in total) you will invest in the stock, then buy 1/4 or 1/3 or 1/2 of your eventual total planned position, and then plan to average in on pullbacks. They ALWAYS come, no stock moves in a straight line (with rare exceptions, lol).
Don't worry about nailing the bottom for a long position (or the top for a short). There is NO PERFECT ENTRY (or exit). Worrying about overpaying by a buck or two, when you expect to make 20-30 bucks, is just silly, imo.
Cheers back at ya!
Not really concerned with who and who does not believe me. I guess if I were lying, I could have done just that - claimed my buy was at the low. I'm good, but not that good. :) Just felt like sharing my joy with the board, after a long trip home. This board had been like a ghost town, and hopefully that will change now. Good things are on tap.
Good luck in your trading.
Walgreen Co (NYSE: WAG) reported a 6% rise in its first-quarter sales.
Walgreen's quarterly sales surged to $18.35 billion , versus $17.32 billion , in the year-ago quarter. Its same-store sales climbed 5.5% in the quarter.
Walgreen's November sales gained 4.1% to $6.07 billion from $5.83 billion , while same-store sales climbed 3.2% in November.
In the pharmacy section, Walgreen's same-store sales surged 4%, versus analysts' expectations for a 3.9% growth.
Keep the good news coming, WAG.
How's this for a welcome home? I get off a plane, and my phone and tablet are both blowing up, lol.
I had shorted this as soon as I was able to (as I often do with overpriced IPOs (as I think this one was)), and rode it down to 14 before I covered. As it got to 12, I started thinking about taking a long pos. Finally, I went long at 13 last week, and look what I get for an early Xmas present today!! I'll take it. :)
I'm going to begin taking half off my pos, and let the rest run a while. Congrats all, let's enjoy this.
For your agitation, and for ultimately getting this deal killed. This was always a horrible deal for PIP shareholders, as initially evidenced by their unwillingness to share details with us for 2 months after first announcing the merger. Management should be ashamed of themselves.
Here's hoping to a quick resolution of the SIGA suit, so we can get paid. :)
Nah, you are doing that quite well, all by yourself. While I applaud you for taking on the board's biggest loser (flute) it's a wasted effort. Even if you DID have some talent at it, he can't be shamed into stopping, so stop wasting your time and making yourself look like an idiot.
How many times is enough? Can you tone the AMRN talk down, or take it to their board? Once should have been enough.
This is such a no-brainer, you have to wonder what's on people's minds when they sell here. Yeah, many were in in the low 2's but the right play to is to take 1/3 or 1/2 off to lock in gains, and let the rest run.
Still long and strong, averaged in around $2.30ish. From my cold, dead hands. :)
Probably nothing more nefarious than they didn't finalize their appearance until late, for whatever reasons. ZIOP just today announced their presence at the Piper conference on the 3rd, and they also usually announce much longer in advance. Perhaps the holiday caused some to waver until the last minute as to whether they'd present. Probably nothing to concern ourselves with, imo.
Infused therapies for the treatment of acute and chronic conditions (such as immune deficiencies, rheumatoid arthritis, multiple sclerosis and nutritional deficiencies) can be administered in many settings - including hospitals, physician's offices, infusion centers and patients' homes. However, costs related to where the drug is administered can vary significantly. A CVS Caremark analysis demonstrates that providing infusion services in the home or an ambulatory setting are by far the most cost-effective sites of service.
" CVS Caremark and Coram share a mutual commitment to provide patients with quality care," said John G. Figueroa , Chief Executive Officer of Coram LLC and Chairman of the Board of Directors for Apria Healthcare Group . "Coram has a demonstrated track record of providing access to infusion services delivered by experienced and knowledgeable clinical staff."
The acquisition is consistent with CVS Caremark's goal of investing in core businesses that help drive growth. Coram is expected to generate approximately $1.4 billion in revenues during the first twelve months following the close of the deal. Including one-time transaction and integration costs, the transaction is expected to have an immaterial impact on CVS Caremark's overall financial results in 2014. The transaction is expected to add $0.03 to $0.05 cents to the Company's Adjusted Earnings Per Share in 2015, the first full year following the close of the deal. The deal is subject to customary closing conditions, including necessary regulatory approvals, and is expected to close by the end of the first quarter of 2014.
As I've been saying for a year, I still think they end up buying RAD.
CVS Caremark (NYSE: CVS) today announced it has entered into an agreement to acquire Coram LLC ("Coram"), the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. for approximately $2.1 billion . Coram is one of the nation's largest providers of comprehensive infusion services, providing infusion therapies and nutrition services to more than 20,000 patients each month. Coram cares for patients primarily through home infusion as well as a national network of more than 85 locations, including more than 65 ambulatory infusion suites.
President of CVS Caremark Pharmacy Services, Jon Roberts said, "Bringing together CVS Caremark's unique range of specialty pharmacy services with Coram's infusion capabilities will expand our competitive offerings in the specialty arena. Infusion will be a valuable component of our broad specialty pharmacy offering going forward. Our comprehensive services will enable us to streamline care management for patients as well as their physicians, leading to better health outcomes while avoiding unnecessary costs."
Costs related to infusion of specialty medications may be covered through the medical or pharmacy benefit, depending on the site of care. CVS Caremark's approach to specialty pharmacy is to bring the most complete set of services to clients and patients, including new approaches to improve management of specialty pharmacy costs that are covered by the medical benefit as well as specialty pharmacy costs that are covered by the pharmacy benefit.
As posted almost a year ago, and again on 9/20 when I took off half my position. Still long and strong. Still wish the pumpers with their 10 and 20 targets near term would calm the phack down, but I digress. :)
^^ (those are my raised hands)